In this video from MD Magazine, Dr. Larry Altstiel, the chief medical officer from vTv Therapeutics talks about his research team’s two Phase 3 Alzheimer’s disease clinical trials. They’re both studying a therapy that targets the receptor for advanced glycation endproducts (RAGE).
Altstiel explains that the Phase 2b study looked at 400 patients with mild to moderate Alzheimer’s disease and found that the molecule they were testing had a “robust” effect on cognitive decline. The FDA have granted Altstiel and his team fast-track status in their upcoming Phase 3 trial, which is due to start in 2018 and will again test two groups of 400 Alzheimer’s patients — one group will take the new therapy and the other will take a placebo.
Alzheimer’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?